Messenger RNA (mRNA) News and Research

RSS

New COVID-19 vaccine promises vaccine equity because it has no patents

Corbevax, a new vaccine against COVID-19, may have better success as a candidate for vaccine equity because it carries no patents, relies on long-established recombinant technology for manufacture and has the support of the US and Indian governments, its makers and health experts say.

21 Jan 2022

Researchers develop nanotherapeutic drug to prevent cancer from spreading to the liver

Physician researchers from UT Southwestern Medical Center have developed an innovative nanotherapeutic drug that prevents cancer from spreading to the liver in mice.

19 Jan 2022

New perspective on SARS-CoV-2 breakthrough infections and booster shot restoration of vaccine efficacy

A recent article published in the journal Science explains how SARS-CoV-2 variants can bypass vaccine-induced immune defenses. However, immunity is restorable with a booster shot. The paper's authors outlined the importance of a booster shot in maintaining immunity and preventing severe infection.

18 Jan 2022

Lack of evidence cross-reactive adaptive immune response is mechanism underlying COVID vaccine-induced myocarditis

Recently, the researchers from the USA, in their study published in the journal EBioMedicine, have conducted a sequence identity comparison and 3D protein structure comparison between the SARS-CoV-2 spike protein-derived peptides/protein and myocarditis-associated antigens and have found no significant enrichment in the frequency of spike-derived peptides similar to myocarditis-associated antigens that could have resulted in adaptive autoimmune responses leading to myocarditis.

12 Jan 2022

SARS-CoV-2 levels decrease when human SIRT5 is deleted or inhibited

Researchers examine the role of human sirtuin 5 (SIRT5) in SARS-CoV-2 infection.

10 Jan 2022

Lab engineered human A549 lung cell model conducive for investigating SARS-CoV-2 antivirals

Researchers developed a human A549 lung epithelial cell-based model to probe SARS-CoV-2 replication.

9 Jan 2022

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, today announced the first participant has been dosed in the Phase 1 study of mRNA-1189, the Company's Epstein-Barr Virus vaccine candidate.

7 Jan 2022

Curia unveils comprehensive mRNA solution

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today unveiled its messenger RNA solution, which includes discovery, process development and mRNA drug substance production, through large-scale lipid manufacturing, lipid nanoparticle formulation and development for full-scale sterile fill-finish services.

From Curia Global, Inc. 7 Jan 2022

New approach with mRNA preparation reprograms T cells to attack heart fibroblasts

An experimental immunotherapy can temporarily reprogram patients' immune cells to attack a specific target via only a single injection of messenger RNA (mRNA), similar to the mRNA-based COVID-19 vaccines, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

6 Jan 2022

Transplant recipients benefit from a COVID-19 vaccine booster

A new preprint research paper posted to the medRxiv* server describes the reduction in humoral immunity in SOTR following vaccination, as well as the improvement with an additional dose of the vaccine.

4 Jan 2022

Echinacea, a potent antiviral against SARS-CoV-2

Researchers present available evidence on the activity of Echinacea purpure against coronavirus infections.

3 Jan 2022

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

New study findings show that the clinical-grade soluble ACE2 effectively inhibits the SARS-CoV-2 Omicron variant, which proves the principle of an effective therapeutic approach against Omicron-driven COVID-19 infections.

30 Dec 2021

An evaluation of the association between COVID vaccination and myocarditis in 42 million people aged 13 or older

A new study posted to the medRxiv* pre-print server included individuals over 13 years of age receiving the third vaccine dose to further evaluate the association between myocarditis and COVID-19 vaccination or infection. The study took place from December 1, 2020, to November 15, 2021.

28 Dec 2021

Single-patient pilot study shows the ability of antisense oligonucleotide to suppress mutant ALS gene

Using a short, synthetic chain of chemically modified nucleotides engineered in the RNA Therapeutics Institute at UMass Chan Medical School, Robert H. Brown Jr., DPhil, MD, Jonathan Watts, PhD, and colleagues have shown the ability to suppress mutant forms of an ALS gene known as C9ORF72 in a single-patient pilot study.

24 Dec 2021

National U.S trial confirms effectiveness of mRNA COVID-19 vaccines

In a recent study, published in the Annals of Internal Medicine, scientists conducted a target trial emulation study and documented that among the elderly in the U.S. (with significant comorbidities), the efficacy of messenger RNA (mRNA) vaccines was much lower in terms of preventing infection, than previously reported. However, the effectiveness against death was found to be high.

21 Dec 2021

Messenger RNA (mRNA) News and Research

New COVID-19 vaccine promises vaccine equity because it has no patents

Researchers develop nanotherapeutic drug to prevent cancer from spreading to the liver

New perspective on SARS-CoV-2 breakthrough infections and booster shot restoration of vaccine efficacy

Lack of evidence cross-reactive adaptive immune response is mechanism underlying COVID vaccine-induced myocarditis

SARS-CoV-2 levels decrease when human SIRT5 is deleted or inhibited

Lab engineered human A549 lung cell model conducive for investigating SARS-CoV-2 antivirals

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Curia unveils comprehensive mRNA solution

New approach with mRNA preparation reprograms T cells to attack heart fibroblasts

Transplant recipients benefit from a COVID-19 vaccine booster

Echinacea, a potent antiviral against SARS-CoV-2

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

An evaluation of the association between COVID vaccination and myocarditis in 42 million people aged 13 or older

Single-patient pilot study shows the ability of antisense oligonucleotide to suppress mutant ALS gene

National U.S trial confirms effectiveness of mRNA COVID-19 vaccines

Long-read RNA sequencing identifies important host immune responses during SARS-CoV-2 infection

Study says COVID mRNA-based vaccines best for booster vaccination

Effectiveness of COVID-19 vaccines among older male veterans

Exploring the impact of DNA nanoswitches in RNA purification

Recycling tubular endosomes are associated with effective delivery of mRNA-based therapeutics, study finds

How to solve the hidden bottleneck in lipid nanoparticle development eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring